Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19
The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory dis...
Gespeichert in:
| Veröffentlicht in: | The European respiratory journal 2020-06, Vol.55 (6), p.2000858 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 6 |
| container_start_page | 2000858 |
| container_title | The European respiratory journal |
| container_volume | 55 |
| creator | Khoury, Maroun Cuenca, Jimena Cruz, Fernanda F Figueroa, Fernando E Rocco, Patricia R M Weiss, Daniel J |
| description | The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations. |
| doi_str_mv | 10.1183/13993003.00858-2020 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7144273</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2387648331</sourcerecordid><originalsourceid>FETCH-LOGICAL-c555t-d540fc41a078f56ba0934651538585aeaa962527e634a968253f1d778012d6c83</originalsourceid><addsrcrecordid>eNpVkcFu2zAMhoWiw5Kme4ICg469uKNES5Z3GFBkW1egQC5br4Jsy40Kx_IkOUDevvaaFN2JBPXzJ6mPkCsGN4wp_MKwLBEAbwCUUBkHDmdkOVezuXxOllACZqxEuSAXMT4DMJkj-0gWyLkUyGBJqvUYgu0TjcmkMVLf0tp2XVaZaBuatjaYwdlIWx9osHFwwSQfDnTvwqR2fWvr5Hwfv1IzDJ2rTeU6lw40ebrePN5_n8Zfkg-t6aL9dIwr8ufnj9_rX9nD5u5-ffuQ1UKIlDUih7bOmYFCtUJWBkrMpWACp-uEscaUkgteWIn5lCousGVNUShgvJG1whX59uo7jNXONvV0VTCdHoLbmXDQ3jj9_0vvtvrJ73XB8pwXOBlcHw2C_zvamPTOxfk3TG_9GDVHVchcIbJJiq_SOvgYg23fxjDQMx19oqP_0dEznanr8_sN33pOOPAFA6uKuw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2387648331</pqid></control><display><type>article</type><title>Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Khoury, Maroun ; Cuenca, Jimena ; Cruz, Fernanda F ; Figueroa, Fernando E ; Rocco, Patricia R M ; Weiss, Daniel J</creator><creatorcontrib>Khoury, Maroun ; Cuenca, Jimena ; Cruz, Fernanda F ; Figueroa, Fernando E ; Rocco, Patricia R M ; Weiss, Daniel J</creatorcontrib><description>The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.</description><identifier>ISSN: 0903-1936</identifier><identifier>EISSN: 1399-3003</identifier><identifier>DOI: 10.1183/13993003.00858-2020</identifier><identifier>PMID: 32265310</identifier><language>eng</language><publisher>England: European Respiratory Society</publisher><subject>Angiotensin-Converting Enzyme 2 ; Animals ; Betacoronavirus ; Cell- and Tissue-Based Therapy ; Coronavirus Infections - therapy ; COVID-19 ; Culture Media, Conditioned ; Extracellular Vesicles - transplantation ; Humans ; Influenza A Virus, H5N1 Subtype ; Influenza A Virus, H9N2 Subtype ; Influenza, Human - therapy ; Lung Injury - therapy ; Lung Injury - virology ; Mesenchymal Stem Cell Transplantation - methods ; Mesenchymal Stem Cells - metabolism ; Orthomyxoviridae Infections - therapy ; Pandemics ; Peptidyl-Dipeptidase A - metabolism ; Pneumonia, Viral - therapy ; Respiratory Distress Syndrome - therapy ; Reviews ; SARS-CoV-2 ; Serine Endopeptidases - metabolism</subject><ispartof>The European respiratory journal, 2020-06, Vol.55 (6), p.2000858</ispartof><rights>Copyright ©ERS 2020.</rights><rights>Copyright ©ERS 2020 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c555t-d540fc41a078f56ba0934651538585aeaa962527e634a968253f1d778012d6c83</citedby><cites>FETCH-LOGICAL-c555t-d540fc41a078f56ba0934651538585aeaa962527e634a968253f1d778012d6c83</cites><orcidid>0000-0002-9965-6266 ; 0000-0002-9387-094X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32265310$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khoury, Maroun</creatorcontrib><creatorcontrib>Cuenca, Jimena</creatorcontrib><creatorcontrib>Cruz, Fernanda F</creatorcontrib><creatorcontrib>Figueroa, Fernando E</creatorcontrib><creatorcontrib>Rocco, Patricia R M</creatorcontrib><creatorcontrib>Weiss, Daniel J</creatorcontrib><title>Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19</title><title>The European respiratory journal</title><addtitle>Eur Respir J</addtitle><description>The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.</description><subject>Angiotensin-Converting Enzyme 2</subject><subject>Animals</subject><subject>Betacoronavirus</subject><subject>Cell- and Tissue-Based Therapy</subject><subject>Coronavirus Infections - therapy</subject><subject>COVID-19</subject><subject>Culture Media, Conditioned</subject><subject>Extracellular Vesicles - transplantation</subject><subject>Humans</subject><subject>Influenza A Virus, H5N1 Subtype</subject><subject>Influenza A Virus, H9N2 Subtype</subject><subject>Influenza, Human - therapy</subject><subject>Lung Injury - therapy</subject><subject>Lung Injury - virology</subject><subject>Mesenchymal Stem Cell Transplantation - methods</subject><subject>Mesenchymal Stem Cells - metabolism</subject><subject>Orthomyxoviridae Infections - therapy</subject><subject>Pandemics</subject><subject>Peptidyl-Dipeptidase A - metabolism</subject><subject>Pneumonia, Viral - therapy</subject><subject>Respiratory Distress Syndrome - therapy</subject><subject>Reviews</subject><subject>SARS-CoV-2</subject><subject>Serine Endopeptidases - metabolism</subject><issn>0903-1936</issn><issn>1399-3003</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkcFu2zAMhoWiw5Kme4ICg469uKNES5Z3GFBkW1egQC5br4Jsy40Kx_IkOUDevvaaFN2JBPXzJ6mPkCsGN4wp_MKwLBEAbwCUUBkHDmdkOVezuXxOllACZqxEuSAXMT4DMJkj-0gWyLkUyGBJqvUYgu0TjcmkMVLf0tp2XVaZaBuatjaYwdlIWx9osHFwwSQfDnTvwqR2fWvr5Hwfv1IzDJ2rTeU6lw40ebrePN5_n8Zfkg-t6aL9dIwr8ufnj9_rX9nD5u5-ffuQ1UKIlDUih7bOmYFCtUJWBkrMpWACp-uEscaUkgteWIn5lCousGVNUShgvJG1whX59uo7jNXONvV0VTCdHoLbmXDQ3jj9_0vvtvrJ73XB8pwXOBlcHw2C_zvamPTOxfk3TG_9GDVHVchcIbJJiq_SOvgYg23fxjDQMx19oqP_0dEznanr8_sN33pOOPAFA6uKuw</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Khoury, Maroun</creator><creator>Cuenca, Jimena</creator><creator>Cruz, Fernanda F</creator><creator>Figueroa, Fernando E</creator><creator>Rocco, Patricia R M</creator><creator>Weiss, Daniel J</creator><general>European Respiratory Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9965-6266</orcidid><orcidid>https://orcid.org/0000-0002-9387-094X</orcidid></search><sort><creationdate>20200601</creationdate><title>Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19</title><author>Khoury, Maroun ; Cuenca, Jimena ; Cruz, Fernanda F ; Figueroa, Fernando E ; Rocco, Patricia R M ; Weiss, Daniel J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c555t-d540fc41a078f56ba0934651538585aeaa962527e634a968253f1d778012d6c83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiotensin-Converting Enzyme 2</topic><topic>Animals</topic><topic>Betacoronavirus</topic><topic>Cell- and Tissue-Based Therapy</topic><topic>Coronavirus Infections - therapy</topic><topic>COVID-19</topic><topic>Culture Media, Conditioned</topic><topic>Extracellular Vesicles - transplantation</topic><topic>Humans</topic><topic>Influenza A Virus, H5N1 Subtype</topic><topic>Influenza A Virus, H9N2 Subtype</topic><topic>Influenza, Human - therapy</topic><topic>Lung Injury - therapy</topic><topic>Lung Injury - virology</topic><topic>Mesenchymal Stem Cell Transplantation - methods</topic><topic>Mesenchymal Stem Cells - metabolism</topic><topic>Orthomyxoviridae Infections - therapy</topic><topic>Pandemics</topic><topic>Peptidyl-Dipeptidase A - metabolism</topic><topic>Pneumonia, Viral - therapy</topic><topic>Respiratory Distress Syndrome - therapy</topic><topic>Reviews</topic><topic>SARS-CoV-2</topic><topic>Serine Endopeptidases - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khoury, Maroun</creatorcontrib><creatorcontrib>Cuenca, Jimena</creatorcontrib><creatorcontrib>Cruz, Fernanda F</creatorcontrib><creatorcontrib>Figueroa, Fernando E</creatorcontrib><creatorcontrib>Rocco, Patricia R M</creatorcontrib><creatorcontrib>Weiss, Daniel J</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The European respiratory journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khoury, Maroun</au><au>Cuenca, Jimena</au><au>Cruz, Fernanda F</au><au>Figueroa, Fernando E</au><au>Rocco, Patricia R M</au><au>Weiss, Daniel J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19</atitle><jtitle>The European respiratory journal</jtitle><addtitle>Eur Respir J</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>55</volume><issue>6</issue><spage>2000858</spage><pages>2000858-</pages><issn>0903-1936</issn><eissn>1399-3003</eissn><abstract>The severe respiratory consequences of the coronavirus disease 2019 (COVID-19) pandemic have prompted urgent need for novel therapies. Cell-based approaches, primarily using mesenchymal stem (stromal) cells (MSCs), have demonstrated safety and possible efficacy in patients with acute respiratory distress syndrome (ARDS), although they are not yet well studied in respiratory virus-induced ARDS. Limited pre-clinical data suggest that systemic MSC administration can significantly reduce respiratory virus (influenza strains H5N1 and H9N2)-induced lung injury; however, there are no available data in models of coronavirus respiratory infection.There is a rapidly increasing number of clinical investigations of cell-based therapy approaches for COVID-19. These utilise a range of different cell sources, doses, dosing strategies and targeted patient populations. To provide a rational strategy to maximise potential therapeutic use, it is critically important to understand the relevant pre-clinical studies and postulated mechanisms of MSC actions in respiratory virus-induced lung injuries. This review presents these, along with consideration of current clinical investigations.</abstract><cop>England</cop><pub>European Respiratory Society</pub><pmid>32265310</pmid><doi>10.1183/13993003.00858-2020</doi><orcidid>https://orcid.org/0000-0002-9965-6266</orcidid><orcidid>https://orcid.org/0000-0002-9387-094X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0903-1936 |
| ispartof | The European respiratory journal, 2020-06, Vol.55 (6), p.2000858 |
| issn | 0903-1936 1399-3003 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7144273 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals |
| subjects | Angiotensin-Converting Enzyme 2 Animals Betacoronavirus Cell- and Tissue-Based Therapy Coronavirus Infections - therapy COVID-19 Culture Media, Conditioned Extracellular Vesicles - transplantation Humans Influenza A Virus, H5N1 Subtype Influenza A Virus, H9N2 Subtype Influenza, Human - therapy Lung Injury - therapy Lung Injury - virology Mesenchymal Stem Cell Transplantation - methods Mesenchymal Stem Cells - metabolism Orthomyxoviridae Infections - therapy Pandemics Peptidyl-Dipeptidase A - metabolism Pneumonia, Viral - therapy Respiratory Distress Syndrome - therapy Reviews SARS-CoV-2 Serine Endopeptidases - metabolism |
| title | Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19 |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-10T05%3A43%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20status%20of%20cell-based%20therapies%20for%20respiratory%20virus%20infections:%20applicability%20to%20COVID-19&rft.jtitle=The%20European%20respiratory%20journal&rft.au=Khoury,%20Maroun&rft.date=2020-06-01&rft.volume=55&rft.issue=6&rft.spage=2000858&rft.pages=2000858-&rft.issn=0903-1936&rft.eissn=1399-3003&rft_id=info:doi/10.1183/13993003.00858-2020&rft_dat=%3Cproquest_pubme%3E2387648331%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2387648331&rft_id=info:pmid/32265310&rfr_iscdi=true |